Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee agrees with the Office of Generic Drugs that bioequivalence standards should be tighter for generic versions of "critical dose" or "narrow therapeutic index" drugs.
You may also be interested in...
Bioequivalence Margins Do Not Need Revision For All Generics, Panel Says
While narrower bioequivalence margins might be necessary for certain categories of generic drugs, FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee has determined that the specifications should not be tightened across the board for all generic drug approvals
Bioequivalence Margins Do Not Need Revision For All Generics, Panel Says
While narrower bioequivalence margins might be necessary for certain categories of generic drugs, FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee has determined that the specifications should not be tightened across the board for all generic drug approvals
Committee Rejects FDA Proposal To Narrow Bioequivalence Margins
The Pharmaceutical Science and Clinical Pharmacology Advisory Committee doesn't see the additional criteria as necessary, but FDA could still impose narrower bioequivalence margins over its objections.